Preclinical study demonstrates that paeonol mitigates oxidative stress and retinal inflammation in diabetic models, indicating its therapeutic potential for diabetic retinopathy.
This study aimed to investigate the protective mechanism of paeonol against diabetic retinopathy (DR) via modulation of the Nrf2/NF-κB signaling pathway. Primary mouse retinal Müller cells exposed to high glucose (HG) and streptozotocin-induced diabetic mice were used as in vitro and in vivo models, respectively. Key techniques included RT-qPCR, Western blot, DCFH-DA-based ROS assays, and ELISA. Paeonol (40-80 μg/ml) significantly reduced HG-induced ROS accumulation (p < 0.01) and restored Nrf2 nuclear translocation, upregulating antioxidant genes HO-1 and NQO1 (p < 0.01). It suppressed NF-κB activation (p-IκBα and p-p65 reduction; p < 0.001) and proinflammatory cytokines (TNF-α, IL-1β, IL-6; p < 0.01) in Müller cells and diabetic retinas. Blood-retinal barrier (BRB) integrity was preserved via upregulation of tight junction proteins (claudin-5, occludin, ZO-1; p < 0.01). In conclusion, paeonol attenuates DR progression by activating Nrf2-mediated antioxidant responses and inhibiting NF-κB-driven inflammation, highlighting its potential as a novel therapeutic agent for DR.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: